Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ferro Pfanstiehl Commissions New Facility | Contract Pharma

What are you searching for?

Sign in
Breaking News

Ferro Pfanstiehl Commissions New Facility

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Ferro Pfanstiehl Labs, Inc., part of the Organic Specialties Group of Ferro Corp., has commissioned a new cGMP supercritical fluid-based particle engineering pilot facility. The facility brings additional expertise in particle sizing, purification and formulation to fee-for-service pharmaceutical and biopharmaceutical customers. It will provide ICH Q7A-compliant small-scale manufacturing of drug particles and compounds for use in Phase I and II trials and feasibility studies of engineered particles for any desired drug delivery application.

Ferro Corp.’s supercritical fluid (SCF) technologies utilize low-cost carbon dioxide to produce nano- and micro-particles with a narrow size distribution and consistent morphology. The particles manufactured using these technologies can be used in controlled release, taste masking, respiratory, transdermal and injectable drug delivery applications. Manufacturing benefits include reduced operating costs, near elimination of waste streams, easy recycling of organic solvents, and reduced cycle time.

“Ferro Pfanstiehl’s cGMP SCF particle engineering facility is unique in offering a full tool box of technical approaches that will enable our customers to solve varied problems in drug development and delivery,” said Peter Thomas, Ferro vice president of organic specialties. “It will allow them to develop and manufacture drug particles suitable for the fastest-growing drug delivery methods, such as inhalable, controlled release and injectable targeted therapeutics.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics